Artificial Intelligence
Among the Chinese AI firms raising new funding, Deep Intelligent Pharma has bagged a total of $110m in two rounds of funding since last December, while Levinthal, OxTium and Aureka have also closed new investment rounds.
Cardiovascular disease is moving to the top of the EU’s health agenda with the release of the Safe Hearts Plan, European Parliament scrutiny of which is expected at the end of Q1. Medical device companies applaud the initiative but will seek more input as the plan evolves.
With capital being recycled, tariffs settling and interest rates softening, 2026 could provide more investment and growth opportunities in pharma and medtech, with AI giving a tailwind, say Taylor Wessing’s Ross McNaughton and Sarah Cole.
Sunshine Pharma plans to invest at least $14m to set up a joint venture with fellow Chinese firm XtalPi, with goals including the discovery and development of novel molecules for autoimmune disorders.
UK major will bag CSPC’s eight preclinical drug candidates in weight management, including most advanced asset SYH2082, a long-acting GLP-1/GIP receptor agonist with once-monthly dosing potential.
Conclusion of India-EU talks sets ground for a free trade agreement to cut pharma tariffs, in turn lowering the cost for novel drugs like Novo’s obesity treatment Wegovy, though an investment protection agreement – likely influencing data exclusivity – will be concluded later.
An India-EU trade deal sets ground for a free trade agreement to lower tariffs on pharma, though an investment protection agreement – likely influencing data exclusivity – will be concluded later. Will the US now reconsider its India tariffs?
Medable pivots to agentic AI targeting clinical development's 80% manual labor bottleneck, aiming to double CRA efficiency and unlock capacity for 9,000 waiting drug candidates.
A joint pilot between Phlow and AI biotech Enveda suggests high-quality data and deep learning could cut Phlow’s active pharmaceutical ingredient development from years to months.
Execs at Biotech Showcase debated business models and platform monetization strategies for AI drug discovery companies, with some arguing they should develop internal pipelines and others advocating for partnership models.
With capital being recycled, tariffs settling and interest rates softening, 2026 could provide more investment and growth opportunities in pharma and medtech, with AI giving a tailwind, say Taylor Wessing’s Ross McNaughton and Sarah Cole.
Execs at Biotech Showcase debated business models and platform monetization strategies for AI drug discovery companies, with some arguing they should develop internal pipelines and others advocating for partnership models.